NBI-1117568 muscarinic agonist starts Phase 2 trials

Neurocrine announces phase 2 trial of NBI-1117568 muscarinic med. Might be similar to KarXT.
https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-initiates-phase-2-clinical-study

Trial link:
https://clinicaltrials.gov/ct2/show/NCT05545111?term=neurocrine&recrs=ab&cond=schizophrenia&draw=2&rank=1
NBI-1117568 is an oral, investigational muscarinic M4 agonist. Muscarinic receptors are central to brain function and validated as drug targets in psychosis and cognitive disorders. As a selective M4 orthosteric agonist, NBI-1117568 offers the potential for an improved safety profile without the need of combination therapy to minimize side effects and avoids the need of cooperativity with acetylcholine (ACh) when compared to non-selective muscarinic agonists and positive allosteric modulators in development.

5 Likes

Yeab i think karxt agonizes ma to m5 receptor while this only agonizes the m4. So it would be an improvement. With karxt you gotta use that tropsium chloride tovantagonize m2 m3 and m5 i think. So this drug sounds superior in theory.

Wont know how good they are unless i actually try them though.

2 Likes

If it works, it might be better than KarXT. Starting phase 2 now, 2028 is possible.

1 Like

I’m reguards to KARxt It says it immediately aliviates “sick behavior” from everything I’ve read it seems pretty incredible. I also don’t think they have measured how it affects negative symptoms yet I think (and I might be wrong) the Panns scores are based on how well it stacks up to other antipsychotics in terms of positive symptoms.

Anyway…I got accepted into the clinical trial for it in Washington and will be going.

2 Likes

Do you have any good links about karxt? All the information and article I’ve found have been pretty cryptic.

I just know that they’re gonna market it towards a variety of conditions. Anything really from ADHD bipolar depression to alcoholism and addiction, as these conditions in one form or another play a role in schiz or development of schiz and negative symptoms. I know the CEO of the company saw such potential and benefit from the original drug that he made it his mission to get it out into the world. Everybody is pretty much just raving about it. I’ll try to find some specific articles about it. They call it a more holistic approach to treating schiz and related psychosis.

1 Like

@Johnnrocato56
Do you get paid to be in clinical trial? If yes, how much? Are you gonna take orher antipsychotics while on it? Let us know how it goes. Finally we got someone on the clinical trial of it.

1 Like

So, is this going to be similar to CBD? Which supposedly works on the same receptors? Because it would be a lot better than other aps if it is. What about the taar1 lurontin? Which receptors are going to most significant? The muscarinic or taar1?

I think this will be much stronger and much different than CBD.
I do not think ulotaront has significant muscarinic effect.

2 Likes